GFAP and Brain atrophy: The current study demonstrates that plasma biomarkers of AD pathology (pTau-181) and astrogliosis (GFAP), but not neuronal injury (NfL), may serve as markers of future brain atrophy and cognitive decline among cognitively unimpaired older adults in the community.